tradingkey.logo

tradingkey.logo
怜玢


Glaukos Corp

GKOS
りォッチリストに远加
153.580USD
+1.525+1.00%
終倀 07-24 16:00ET15分遅れの株䟡
9.02B時䟡総額
損倱額盎近12ヶ月PER

詳现情報 Glaukos Corp 䌁業名

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Glaukos Corpの䌁業情報


䌁業コヌドGKOS
䌚瀟名Glaukos Corp
䞊堎日Jun 25, 2015
最高経営責任者「CEO」Burns (Thomas William)
埓業員数995
蚌刞皮類Ordinary Share
決算期末Jun 25
本瀟所圚地1 Glaukos Way
郜垂ALISO VIEJO
蚌刞取匕所NASDAQ OMX NASDAQ Basic NYSE
囜United States of America
郵䟿番号92656
電話番号19493679600
りェブサむトhttps://www.glaukos.com
䌁業コヌドGKOS
䞊堎日Jun 25, 2015
最高経営責任者「CEO」Burns (Thomas William)

Glaukos Corpの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
-0.24%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
47.84K
-1.50%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%
Dr. Gilbert H. (Gil) Kliman, M.D.
Dr. Gilbert H. (Gil) Kliman, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph E. Gilliam
Mr. Joseph E. Gilliam
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Independent Director
Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
-0.24%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
47.84K
-1.50%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%

よくある質問

Glaukos Corpの䞊䜍5名の株䞻は誰ですか


Glaukos Corpの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Thomas William Burns

Glaukos CorpGKOSの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Glaukos Corpの株匏を保有しおいる機関は702瀟あり、保有株匏の総垂堎䟡倀は玄59.35Mで、党䜓の101.04%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-2784097.00増加しおいたす。

Glaukos Corpの最倧の収益源は䜕ですか


2026Q1においお、Glaucoma郚門がGlaukos Corpにずっお最倧の収益を生み出しおおり、その金額は421.07Mで、党収益の82.98%を占めおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。